Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
Abstract
A V1-V2 IgG3 response to HIV correlates with a decreased risk of HIV-1 infection and is one vaccine-induced humoral response that is higher in a clinical trial showing HIV-1 vaccine efficacy compared to a trial showing nonefficacy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 19, 2014
- Source ID
- 10.1126/scitranslmed.3007730
Entities
People
- Abraham Pinter
- Allan C deCamp
- Barton Haynes
- Carter Lee
- David C. Montefiori
- David T. Evans
- Donald Francis
- Faruk Sinangil
- Gary Nabel
- Georgia D. Tomaras
- Guido Ferrari
- Hua-Xin Liao
- James Tartaglia
- Jaranit Kaewkungwal
- Jerome H Kim
- Kelly E. Seaton
- Michael D. Alpert
- Nathan A. Vandergrift
- Nelson Michael
- Nicole L. Yates
- Peter B Gilbert
- Phillip W. Berman
- Punnee Pitisuttithum
- Robert J. O'connell
- S. Munir Alam
- Sorachai Nitayaphan
- Supachai Rerks-ngarm
- Susan Zolla-Pazner
- William T. Williams
- Youyi Fong
- Zhi-yong Yang
Organizations
- Duke University
- Duke University Human Vaccine Institute
- Fred Hutchinson Cancer Center
- Global Solutions for Infectious Diseases
- Harvard Medical School
- Mahidol University
- Ministry of Public Health
- National Institutes of Health
- New York University
- Rutgers University
- Sanofi Pasteur
- University of California, Santa Cruz
- Walter Reed Army Institute of Research